Skip to main content
Smart Investors Daily
AM

NASDAQ · AMLX

Amylyx Pharmaceuticals, Inc.

Healthcare · Biotechnology

$28.04

Up+$0.26 (+0.94%)

Updated Oct 7, 2026, 6:14 AM

SID Score

4.9/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
1.26B
P/E ratio
-9.48
Dividend yield
0.00%
52-week range
$12.44 – $41.14
Volume
1.28M
Avg. volume
1.42M

Price performance · AMLX

AMLX price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Oct 6, 2026

AMLX closed at $28.04 after 21 trading sessions, down 17.24% for the selected period.

Last close
$28.04
Period change
-17.24%
Period low
$27.78
Period high
$33.94
Daily close
View OHLC price history
AMLX OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Oct 6, 2026$27.97$28.4988$27.00$28.041.28M
Oct 5, 2026$27.92$28.09$27.34$27.78941.08K
Oct 2, 2026$28.50$28.81$27.64$27.79912.39K
Oct 1, 2026$28.62$29.28$27.55$28.081.35M
Sep 30, 2026$29.47$29.62$28.64$29.101.31M
Sep 29, 2026$29.87$30.10$28.99$29.281.18M
Sep 28, 2026$29.10$30.14$28.71$29.851.02M
Sep 25, 2026$30.28$30.70$29.47$29.491.29M
Sep 24, 2026$30.73$31.001$29.83$30.141.42M
Sep 23, 2026$32.88$33.02$30.53$30.6051.82M
Sep 22, 2026$32.52$33.19$32.25$33.001.38M
Sep 21, 2026$32.55$33.16$31.90$32.391.01M
Sep 18, 2026$34.21$34.21$32.25$32.412.05M
Sep 17, 2026$33.33$34.345$32.95$33.941.59M
Sep 16, 2026$33.05$33.75$32.095$32.631.37M
Sep 15, 2026$33.22$33.54$32.36$33.151.83M
Sep 14, 2026$31.84$33.955$31.57$33.641.93M
Sep 11, 2026$32.09$33.00$31.37$31.621.71M
Sep 10, 2026$31.81$32.57$31.44$32.091.78M
Sep 9, 2026$33.50$34.35$32.30$32.401.29M
Sep 8, 2026$33.49$34.72$33.10$33.881.17M

Latest AMLX news

The latest Smart Investors Daily articles mentioning AMLX.

AMLX research

Overview

Company profile and research snapshot.

Company profile

Amylyx Pharmaceuticals Inc is a clinical-stage pharmaceutical company working on developing a novel therapeutic for amyotrophic lateral sclerosis and other neurodegenerative diseases. It has one operating segment which is the business of researching and developing therapeutics for neurodegenerative disorder and endocrine conditions.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$20.00
Implied upside
—
Analysts
—
AMLX recent ratings
DateFirmRatingTarget
Aug 27, 2026GuggenheimBuy—
Aug 19, 2026MizuhoOutperform—
Aug 19, 2026GuggenheimBuy—
Aug 19, 2026BairdOutperform—
Aug 18, 2026HC Wainwright & Co.Buy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Sep 25, 2026

Our Pick Of The Best Growth Stocks In September 2026

Bond markets have been shaken by 10-year Treasury yields hitting a 19-year high, which raises borrowing costs and forces investors to rethink where future returns might come from. That kind of reset often shifts attention toward businesses where earnings are expected to grow solidly and balance sheets still look healthy. This article highlights three stocks that fit that profile and explains how they may fit into a long-term growth plan. The three stocks covered next are only a small sample...

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.